0001209191-23-016401.txt : 20230306 0001209191-23-016401.hdr.sgml : 20230306 20230306171206 ACCESSION NUMBER: 0001209191-23-016401 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230302 FILED AS OF DATE: 20230306 DATE AS OF CHANGE: 20230306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nolan Mangini Siobhan CENTRAL INDEX KEY: 0001679464 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38853 FILM NUMBER: 23709883 MAIL ADDRESS: STREET 1: C/O NMG BIOPHARMACEUTICALS, INC. STREET 2: 333 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NGM BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0001426332 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-243-5555 MAIL ADDRESS: STREET 1: 333 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-02 0 0001426332 NGM BIOPHARMACEUTICALS INC NGM 0001679464 Nolan Mangini Siobhan C/O NGM BIOPHARMACEUTICALS, INC. 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 President and CFO Common Stock 2023-03-02 4 A 0 76000 0.00 A 76000 D Stock Option (Right to Buy) 4.36 2023-03-02 4 A 0 228000 0.00 A 2033-03-01 Common Stock 228000 228000 D Stock Option (Right to Buy) 4.36 2023-03-02 4 A 0 200000 0.00 A 2033-03-01 Common Stock 200000 200000 D Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027. The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis. 1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date. /s/ Valerie Pierce, Attorney-in-fact 2023-03-06